There is a lot of excitement with the compounding pharmacy and rightly so. As far as I can see, it is currently the #1 revenue producer for ScripsAmerica with huge, huge, potential. However, I am excited about the multiple revenue streams and the combined potential. Mr. Schneiderman has invested a lot of time and financial resources in the RapiMeds line of business and I believe with the combined OTC potential in China and Canada, RapiMeds will add considerably to the bottom line in the future. One aspect of SCRC I really like is that we are not hinging our success on one product or service. For months with all posted with enthusiasm discussions about the six revenue streams. These six streams of revenue continue to be SCRC's strength for the future we all look forward to. GO SCRC!!!